

GCC Pharmaceutical Market Opportunity Insight 2025

<https://marketpublishers.com/r/G59FEC836F10EN.html>

Date: January 2020

Pages: 300

Price: US\$ 3,600.00 (Single User License)

ID: G59FEC836F10EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'GCC Pharmaceutical Market Opportunity Insight 2025' Report Highlights:

GCC Pharmaceutical Market Opportunity: > US\$ 20 Billion

Patented & OTC Pharmaceutical Market Size: 75% of Total Market

Share of Imported Drugs In GCC Pharmaceutical Market: > 80%

Saudi Arabia Dominates GCC Pharmaceutical Market: 50% Market Share

GCC Pharmaceutical Clinical Trials Insight: > 700 Drugs

The research report 'GCC Pharmaceutical Market Opportunity Insight 2025' provides an in-depth analysis about the current market dynamics that includes drivers, trends and opportunities which are subjected to have an influence on the market of the pharmaceutical products in the GCC region. Various important factors that are supported by the governments of the GCC countries for various agents commercialized in the region are also provided in a segmented way in the research report. The impact of the regulatory scenario that is prevailing upon the major key players of the region is also discussed in the report.

The research conducted on the respective subject highlights the distribution of the market based on the profiles of the companies and their respective efforts in increasing the production and value of the product exponentially. The anticipation of the pharmaceutical market in the GCC region is believed to be the result of the factors that

are hindering the people of GCC region such as rapid change in the dynamics of the population, geriatric population and most importantly increasing prevalence of lifestyle associated diseases such as diabetes, obesity, cardiovascular diseases.

'GCC Market Offers Unexplored & Exponential Growth Opportunities For Global Pharmaceutical Companies As Imports Accounts For More Than 80% Regional Pharmaceutical Products Sales.'

With the increasing disorders associated with lifestyle of the gulf population, the government policies along with regulatory framework became more poised towards the promoting the growth of the pharmaceutical market in the region. Factors like these are most prominent in developing a huge difference and marking an exponential growth rate in the market size of GCC pharmaceutical market in the coming years. Over the years, the branded drugs market has been dominating the market of GCC pharmaceuticals and most pre-dominantly among all the countries included in GCC, Saudi Arabia compiled of maximum share of the market.

Saudi Arabia, among the other gulf countries is a region with major dominant traits. Economic viability, changing legislative and framework are the main driving forces for the establishment of such high-valued pharmaceutical market in the gulf. Slowly and steadily, new frontiers of the pharmaceutical market are making their way to the gulf and imposing their need for the development of generic drug over the market of branded drugs. The alternative form of the drugs available in the market will end up in the up-regulation of the overall market trends by many folds.

“The Growing Demand Of The Generic And Branded Pharmaceuticals That Is Driven By The Various Government Policies And Cost Effective Facilities, Is Considered As A Significant Opportunity For The Drug Manufacturers In The GCC.”

The sales record achieved from the gulf countries establishes Saudi Arabia as an emerging ground for the pharmaceutical market, with UAE and others as a prominent region for expanding the market. The Imported drug market established in the region constitutes a major portion of the GCC pharmaceutical market. More than 80% of the drug utilized in the gulf countries is imported from the major players established in the Western countries. The percent mentioned indicates a huge demand of the drugs either imported or manufactured in the local region. Both aspects of the pharmaceutical market suggest a high demand of the pharmaceutical drugs in the market and eventually a prevailing commercial success.

Contents

1. INTRODUCTION TO GULF COOPERATION COUNCIL (GCC) PHARMACEUTICAL MARKET

- 1.1 Overview
- 1.2 GCC Pharmaceutical Market Analysis

2. GCC PHARMACEUTICAL MARKET BY INDICATION - PREVALENCE & STATISTICS

- 2.1 Cancer
 - 2.1.1 Overview
 - 2.1.2 Prevalence by Cancer Type & Gender
 - 2.1.3 Cancer Prevalence & Statistics by GCC Countries
- 2.2 Diabetes
- 2.3 HIV/AIDS
- 2.4 Cardiovascular Diseases
 - 2.4.1 Coronary Heart Disease
 - 2.4.2 Hypertension
 - 2.4.3 Stroke
- 2.5 Obesity
- 2.6 Respiratory Disorders
 - 2.6.1 Asthma
 - 2.6.2 Tuberculosis
 - 2.6.3 Influenza & Pneumonia
 - 2.6.4 Other Respiratory Diseases - COPD & Cystic Fibrosis
- 2.7 Alzheimer's Disease/Dementia

3. GCC - REGULATORY ASPECTS OF PHARMACEUTICALS

- 3.1 Gulf Central Committee for Drug Registrations (GCC-DR)
- 3.2 Regulatory Review Process
- 3.3 Centralized Registration
- 3.4 Decentralized Drug Registration Regulation
 - 3.4.1 Saudi Arabia
 - 3.4.2 Kuwait
 - 3.4.3 UAE
 - 3.4.4 Bahrain

- 3.4.5 Qatar
- 3.4.6 Oman
- 3.5 Gulf Joint Procurement Program

4. GCC - PHARMACEUTICAL PRICING & REIMBURSEMENT POLICIES

- 4.1 Pricing Policies
 - 4.1.1 In-Patent Pharmaceuticals
 - 4.1.2 Off-Patent & Generic Pharmaceuticals
 - 4.1.3 Locally & Multinational Manufactured Pharmaceuticals
- 4.2 Procurement & Reimbursement Policies
 - 4.2.1 In-Patent Pharmaceuticals
 - 4.2.2 Off-Patent, Generics & Biosimilars

5. GCC PHARMACEUTICAL MARKET BY PRODUCT

- 5.1 Generics Pharmaceuticals
- 5.2 Patented & OTC Pharmaceuticals
- 5.3 Biosimilars

6. SAUDI ARABIA PHARMACEUTICAL MARKET ANALYSIS

- 6.1 Overview
- 6.2 Saudi Arabia Pharmaceutical Market by Products
- 6.3 Saudi Arabia Pharmaceutical Market by Companies
- 6.4 Saudi Arabia Pharmaceutical Market by Type

7. UAE PHARMACEUTICAL MARKET ANALYSIS

- 7.1 Overview
- 7.2 UAE Pharmaceuticals Market by Product
- 7.3 UAE Pharmaceutical Market by Companies
- 7.4 UAE Pharmaceutical Market by Type

8. KUWAIT PHARMACEUTICAL MARKET ANALYSIS

- 8.1 Overview
- 8.2 Kuwait Pharmaceutical Market by Therapeutic Indication & Products
- 8.3 Kuwait Pharmaceutical Market by Companies

8.4 Kuwait Pharmaceutical Market by Type

9. BAHRAIN PHARMACEUTICAL MARKET ANALYSIS

9.1 Overview

9.2 Bahrain Pharmaceutical Market by Products

9.3 Bahrain Pharmaceutical market by Companies

9.4 Bahrain Pharmaceutical Market by Product Type

10. QATAR PHARMACEUTICAL MARKET ANALYSIS

10.1 Overview

10.2 Qatar Pharmaceutical Market by Type

11. OMAN PHARMACEUTICAL MARKET ANALYSIS

11.1 Overview

11.2 Oman Pharmaceutical Market by Product Type

12. GCC PHARMACEUTICAL MARKET - INTERNATIONAL TRADE

12.1 Import Market

12.2 Pharmaceutical Export Market

13. GCC PHARMACEUTICAL MARKET - CLINICAL INSIGHT

13.1 Overview

13.2 Clinical Trials by Indication

13.2.1 Cancer

13.2.2 Diabetes

13.2.3 CVS Disorders

13.2.4 Respiratory Disorders

13.3 Clinical Insight by GCC Countries

13.3.1 Saudi Arabia

13.3.2 United Arab Emirates

13.3.3 Kuwait

13.3.4 Bahrain

13.3.5 Qatar

13.3.6 Oman

14. GCC PHARMACEUTICAL MARKET DRIVERS

15. CHALLENGES FOR GCC PHARMACEUTICAL MARKET

16. GCC PHARMACEUTICAL MARKET FUTURE OUTLOOK - TRENDS & OPPORTUNITIES

17. COMPETITIVE LANDSCAPE

17.1 Local Pharmaceutical Companies

- 17.1.1 Julphur Pharmaceuticals
- 17.1.2 SPIMACO Addwaeih
- 17.1.3 Qatar Life Pharma
- 17.1.4 Al Mojil Drug Company
- 17.1.5 Kuwait Saudi Pharmaceutical Company
- 17.1.6 YIACO Medical Company
- 17.1.7 Qatar Pharma
- 17.1.8 Saja Pharmaceuticals
- 17.1.9 Oman Pharmaceuticals
- 17.1.10 Taiba Pharmaceuticals
- 17.1.11 Gulf Biotech
- 17.1.12 Bahrain Pharma
- 17.1.13 Neopharma
- 17.1.14 Planet Pharmacies
- 17.1.15 Aljazeera Pharmaceutical Industries
- 17.1.16 Dallah Pharma
- 17.1.17 Tabuk Pharmaceuticals
- 17.1.18 CAD Middle-East Pharmaceutical Company
- 17.1.19 ACDIMA
- 17.1.20 AL-Mufid Pharmaceuticals

17.2 Multinational Companies

- 17.2.1 Novartis
- 17.2.2 Amgen
- 17.2.3 Eli - Lilly
- 17.2.4 Merck
- 17.2.5 Pfizer
- 17.2.6 GlaxoSmithKline plc
- 17.2.7 Roche

17.2.8 Takeda Pharmaceuticals

17.2.9 Teva Pharmaceuticals

17.2.10 AstraZeneca plc

17.2.11 Genentech

17.2.12 Sanofi

List Of Figures

LIST OF FIGURES

- Figure 1-1: Pharmaceutical Market Size - Global vs. GCC (US\$ Billion), 2018
- Figure 1-2: GCC vs. Rest of World - Pharmaceutical Market Size (%), 2018
- Figure 1-3: GCC - Population Statistics (Million), 2019
- Figure 1-4: GCC - Population by Countries (%), 2019
- Figure 1-5: GCC - Healthcare Expenditure by Countries (US\$ Billion), 2018
- Figure 1-6: GCC - Healthcare Expenditure by Countries (%), 2018
- Figure 1-7: GCC - Pharmaceutical Market Size (US\$ Billion), 2016 & 2018
- Figure 1-8: GCC Pharmaceutical Market Size (US\$ Billion), 2018 - 2025
- Figure 1-9: MEA vs. GCC - Pharmaceutical Market Size (US\$ Billion), 2018
- Figure 1-10: GCC vs. Rest of MEA - Pharmaceutical Market Size (%), 2018
- Figure 1-11: GCC - Pharmaceutical Market Size by Countries (US\$ Billion), 2018
- Figure 1-12: Pharmaceutical Market Size of Various GCC Countries (%), 2018
- Figure 2-1: GCC - Number of Newly Diagnosed Cancer Cases & Deaths, 2018
- Figure 2-2: GCC - Number of New Cancer Cases by Countries, 2018
- Figure 2-3: GCC - New Cancer Cases by Countries (%), 2018
- Figure 2-4: GCC - Number of Cancer Related Deaths by Countries, 2018
- Figure 2-5: GCC - New Cancer Cases by Countries (%), 2018
- Figure 2-6: GCC - Number of Newly Diagnosed Cancer Cases, 2018 & 2030
- Figure 2-7: GCC - Age Standardized Cancer Incidence Rate by Countries (per 100,000 People), 2018
- Figure 2-8: GCC - Age Standardized Cancer Mortality Rate by Countries (per 100,000 People), 2018
- Figure 2-9: GCC Pharmaceutical Market Size - Total vs. Cancer Drugs (US\$ Billion), 2018
- Figure 2-10: GCC - Cancer Drug Market Size by Countries (%), 2018
- Figure 2-11: GCC - Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 2-12: GCC - New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-13: GCC - Number of Cancer Cases & Deaths by Gender, 2018
- Figure 2-14: GCC - Cancer Cases by Gender (%), 2018
- Figure 2-15: GCC - Cancer Deaths by Gender (%), 2018
- Figure 2-16: GCC - Age Standardized Cancer Incidence & Mortality Rate (per 100,000 People), 2018
- Figure 2-17: Saudi Arabia - Number of Cancer Cases & Deaths, 2018
- Figure 2-18: Saudi Arabia - Number of Cancer Cases & Deaths by Gender, 2018
- Figure 2-19: Saudi Arabia - New Diagnosed Cancer Cases by Gender (%), 2018

- Figure 2-20: Saudi Arabia - Cancer Related Deaths by Gender (%), 2018
- Figure 2-21: Saudi Arabia - New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-22: UAE - Number of Cancer Cases & Deaths, 2018
- Figure 2-23: UAE - Number of Cancer Cases & Deaths by Gender, 2018
- Figure 2-24: UAE - New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-25: UAE - Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 2-26: Kuwait - Number of Cancer Cases & Deaths, 2018
- Figure 2-27: Kuwait - Number of Cancer Cases & Deaths by Gender, 2018
- Figure 2-28: Kuwait - New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-29: Kuwait - Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 2-30: Bahrain - Number of Cancer Cases & Deaths, 2018
- Figure 2-31: Bahrain - Number of Cancer Cases & Deaths by Gender, 2018
- Figure 2-32: Bahrain - New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-33: Bahrain - Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 2-34: Qatar - Number of Cancer Cases & Deaths, 2018
- Figure 2-35: Qatar - Number of Cancer Cases & Deaths by Gender, 2018
- Figure 2-36: Qatar - New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-37: Qatar - Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 2-38: Oman - Number of Cancer Cases & Deaths, 2018
- Figure 2-39: Oman - Number of Cancer Cases & Deaths by Gender, 2018
- Figure 2-40: Oman - New Diagnosed Cases by Cancer Type (%), 2018
- Figure 2-41: Oman - Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 2-42: GCC - Total Adult Population & Diabetic Population (Million), 2017
- Figure 2-43: GCC - Total Adult Population & Diabetic Population (%), 2017
- Figure 2-44: GCC - Diabetic Population by Countries (Million), 2017
- Figure 2-45: GCC - Diabetic Population by Countries (%), 2017
- Figure 2-46: GCC - Diabetes Related Deaths by Countries, 2017
- Figure 2-47: GCC - Diabetes Related Deaths by Countries (%), 2017
- Figure 2-48: GCC - Diabetes Prevalence Rate by Countries (%), 2017
- Figure 2-49: GCC - Age Standardized Diabetes Death Rate by Countries (Per 100,000 People), 2017
- Figure 2-50: GCC - Diabetic Population (Billion), 2017, 2018 & 2045
- Figure 2-51: Saudi Arabia - Total HIV Cases & Newly Diagnosed HIV Cases, 2017
- Figure 2-52: Saudi Arabia - New Diagnosed HIV Cases, 2013 - 2017
- Figure 2-53: Saudi Arabia - New Diagnosed HIV Cases by Gender, 2017
- Figure 2-54: Saudi Arabia - New Diagnosed HIV Cases by Gender (%), 2017
- Figure 2-55: Saudi Arabia - Total HIV Cases by Gender, 2017
- Figure 2-56: Saudi Arabia - Total HIV Cases by Gender, 2017
- Figure 2-57: Saudi Arabia - Cumulative HIV Related Deaths by Gender, 2017

Figure 2-58: Saudi Arabia - Cumulative Number of HIV Patients on Anti-retroviral Therapy, 2017

Figure 2-59: UAE - Cumulative Number of HIV Patients, 2012, 2014 & 2016

Figure 2-60: UAE - Number of New HIV Cases & Deaths, 2016

Figure 2-61: UAE - Cumulative Number of HIV Patients on Anti-retroviral Therapy, 2012, 2014 & 2018

Figure 2-62: UAE - Cumulative Number of HIV Patients, 2014 - 2018

Figure 2-63: Bahrain - HIV Associated New Cases & Deaths, 2016

Figure 2-64: Bahrain - Patients Receiving Antiretroviral Therapy (%), 2012, 2014 & 2016

Figure 2-65: Qatar - Cumulative Number of HIV Cases & Patients on Antiretroviral Therapy, 1984 - 2014

Figure 2-66: Qatar - HIV Patients on Anti-Retroviral Therapy, 1984 - 2014

Figure 2-67: Oman - Cumulative HIV Cases, 2014, 2016 & 2018

Figure 2-68: Oman - Cumulative HIV Cases by Gender, 2018

Figure 2-69: Oman - Cumulative HIV Cases by Gender (%), 2018

Figure 2-70: Oman - Cumulative HIV Cases by Age, 2018

Figure 2-71: GCC - Age Standardized Coronary Heart Disease Death Rate by Countries, 2017

Figure 2-72: GCC - CHD Related Deaths by Countries, 2017

Figure 2-73: GCC - CHD Related Deaths by Countries (%), 2017

Figure 2-74: GCC - Age Standardized Hypertension Death Rate by Countries, 2017

Figure 2-75: GCC - Hypertension Related Deaths by Countries, 2017

Figure 2-76: GCC - Hypertension Related Deaths by Countries (%), 2017

Figure 2-77: GCC - Age Standardized Stroke Death Rate by Countries, 2017

Figure 2-78: GCC - Stroke Related Deaths by Countries, 2017

Figure 2-79: GCC - Stroke Related Deaths by Countries (%), 2017

Figure 2-80: GCC - Obese Population by Countries (%), 2019

Figure 2-81: GCC - Body Mass Index by Countries, 2019

Figure 2-82: Saudi Arabia - Obesity Prevalence Rate (%), 2017 & 2022

Figure 2-83: Saudi Arabia - Obesity Prevalence Rate by Gender (%), 2017 & 2022

Figure 2-84: UAE - Prevalence Rate of Obesity & Overweight by Gender (%), 2016

Figure 2-85: UAE - Obese Adult Population (%), 2019

Figure 2-86: Kuwait - Prevalence Rate of Obesity & Overweight (%), 2016

Figure 2-87: Kuwait - Prevalence Rate of Obesity & Overweight by Gender (%), 2016

Figure 2-88: Bahrain - Prevalence Rate of Obesity & Overweight (%), 2016

Figure 2-89: Bahrain - Prevalence Rate of Obesity & Overweight by Gender (%), 2016

Figure 2-90: Qatar - Prevalence Rate of Obesity & Overweight (%), 2016

Figure 2-91: Qatar - Prevalence Rate of Obesity & Overweight by Gender (%), 2016

Figure 2-92: Oman - Obesity Prevalence Rate by Gender (%), 2016

- Figure 2-93: GCC - Asthma Related Deaths by Countries, 2017
- Figure 2-94: GCC - Asthma Related Deaths by Countries (%), 2017
- Figure 2-95: GCC - Age Standardized Asthma Death Rate by Countries (per 100,000 People), 2017
- Figure 2-96: GCC - Tuberculosis Related Deaths by Countries, 2017
- Figure 2-97: GCC - Age Standardized Incidence Rate of Tuberculosis by Countries (Per 100,000 People), 2017
- Figure 2-98: GCC - Asthma Related Deaths by Countries (%), 2017
- Figure 2-99: GCC - Age Standardized Tuberculosis Death Rate by Countries (per 100,000 People), 2017
- Figure 2-100: GCC - Influenza & Pneumonia Related Deaths by Countries, 2017
- Figure 2-101: GCC - Influenza & Pneumonia Related Deaths by Countries (%), 2017
- Figure 2-102: GCC - Age Standardized Influenza & Pneumonia Death Rate by Countries (per 100,000 People), 2017
- Figure 2-103: GCC - COPD Prevalence Rate by Countries (%), 2018
- Figure 2-104: GCC - COPD & Cystic Fibrosis Related Deaths by Countries, 2017
- Figure 2-105: GCC - COPD & Cystic Fibrosis Related Deaths by Countries (%), 2017
- Figure 2-106: GCC - Age Standardized COPD & Cystic Fibrosis Death Rate by Countries (per 100,000 People), 2017
- Figure 2-107: GCC - Alzheimer/Dementia Related Deaths by Countries, 2017
- Figure 2-108: GCC - Alzheimer/Dementia Related Deaths by Countries (%), 2017
- Figure 2-109: GCC - Age Standardized Alzheimer/Dementia Death Rate by Countries (per 100,000 People), 2017
- Figure 3-1: GCC - Types of Drug Registration Process
- Figure 3-2: Process Map for GCC Centralized Registration
- Figure 3-3: GCC - Innovative/Biological and Generic Drug Registration Fees for Evaluation Procedures (SAR/US\$), 2019
- Figure 3-4: GCC - Innovative/Biological and Generic Drug Registration Renewal Fees (SAR/US\$), 2019
- Figure 3-5: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Innovative/Biological Products (SAR/US\$), 2019
- Figure 3-6: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Generic Products (SAR/US\$), 2019
- Figure 3-7: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Intravenous Generic Products (SAR/US\$), 2019
- Figure 3-8: Saudi Arabia - Regulatory Process for Pharmaceuticals
- Figure 3-9: Kuwait - Regulatory Process for Pharmaceuticals
- Figure 3-10: UAE - Regulatory Process for Pharmaceuticals
- Figure 3-11: Bahrain - Regulatory Process for Pharmaceuticals

Figure 3-12: Qatar - Regulatory Process for Pharmaceuticals

Figure 3-13: Oman - Regulatory Process for Pharmaceuticals

Figure 5-1: GCC - Pharmaceutical Market Size - Generic vs. Others (US\$ Billion), 2018

Figure 5-2: GCC - Pharmaceutical Market Size - Generic vs. Others (%), 2018

Figure 5-3: GCC - Generic Drug Market Size (US\$ Billion), 2018 - 2025

Figure 5-4: GCC - Patented & OTC Pharmaceutical Market Size (US\$ Billion), 2018

Figure 5-5: GCC - Share of Patented Products in Pharmaceutical Market by Countries (%), 2016

Figure 5-6: GCC - Share of OTC Products in Pharmaceutical Market by Countries (%), 2016

Figure 5-7: GCC - Biosimilars Market Size (US\$ Million), 2019 & 2025

Figure 5-8: GCC - Strategies Considered by New Biosimilars Manufacturers

Figure 5-9: Key Stakeholders for Launch of Biosimilars

Figure 6-1: Pharmaceutical Market Size - Saudi Arabia vs. Rest of GCC (%), 2018

Figure 6-2: Pharmaceutical Market Size - Saudi Arabia vs. Rest of MEA (%), 2018

Figure 6-3: Saudi Arabia - Pharmaceutical Market Size (US\$ Billion), 2018 - 2025

Figure 6-4: Saudi Arabia - Pharmaceutical Market Share by Channel of Distribution (%), 2018

Figure 6-5: Saudi Arabia - Pharmaceutical Market Size by indication (%), 2018

Figure 6-6: Saudi Arabia - Number of New Product Launched by Indication, 2018

Figure 6-7: Saudi Arabia - Sales Data of Leading Pharmaceutical Products (US\$ Million), 2018

Figure 6-8: Saudi Arabia - Revenue of Leading Pharmaceutical Companies (US\$ Million), 2018

Figure 6-9: Saudi Arabia - Generic & Branded Pharmaceutical Market Size (%), 2018

Figure 6-10: Saudi Arabia - OTC & Prescribed Pharmaceuticals Market Size (US\$ Billion), 2018

Figure 6-11: Saudi Arabia - OTC & Prescribed Pharmaceutical Market Size (%), 2018

Figure 7-1: Pharmaceutical Market Size - UAE vs. Rest of GCC (%), 2018

Figure 7-2: Pharmaceutical Market Size - UAE vs. Rest of MEA (%), 2018

Figure 7-3: UAE - Pharmaceutical Market Size by Channel of Distribution (%), 2018

Figure 7-4: UAE - Pharmaceutical Market Size (US\$ Billion), 2018 - 2025

Figure 7-5: UAE - Pharmaceutical Export Market by Region (%), 2017

Figure 7-6: UAE - Pharmaceutical Export Market by Countries (%), 2017

Figure 7-7: UAE - Pharmaceutical Export Market by Products (%), 2018

Figure 7-8: UAE - Pharmaceutical Market Size by Therapeutic Indication (US\$ Million), 2018

Figure 7-9: UAE - Number of New Launched Pharmaceutical Product by Indication, 2018

Figure 7-10: UAE - Growth Rate of Leading Pharmaceutical Companies (%), 2018

Figure 7-11: UAE - Pharmaceutical Market Share by Type of Products (%), 2017

Figure 7-12: UAE - Pharmaceutical Market Share by Type of Products (%), 2018

Figure 7-13: UAE - Generic Drug Market Size (US\$ Million), 2017 - 2025

Figure 8-1: Pharmaceutical Market Size - Kuwait vs. Rest of GCC (%), 2018

Figure 8-2: Pharmaceutical Market Size - Kuwait vs. Rest of MEA (%), 2018

Figure 8-3: Kuwait - Pharmaceutical Market Size (US\$ Billion), 2018-2025

Figure 8-4: Kuwait - Pharmaceutical Market Size by Therapeutic Indication (%), 2018

Figure 8-5: Kuwait - Sales Data of Leading Pharmaceutical Products (US\$ Million), 2018

Figure 8-6: Kuwait - Pharmaceutical Market Size - MNC vs. Regional Companies (%), 2016

Figure 8-7: Kuwait - Julphar Pharmaceutical Share in Regional Pharmaceutical sales (%), 2016

Figure 8-8: Kuwait - Pharmaceutical Market Size by Leading Companies (US\$ Million), 2018

Figure 8-9: Kuwait - Generic Pharmaceutical Market Share (%), 2018 & 2025

Figure 8-10: Kuwait - Pharmaceutical Market by Type of Product (%), 2018

Figure 8-11: Kuwait - Generic Drug Market Share in Total market Size (%), 2018

Figure 8-12: Kuwait - OTC Pharmaceutical Market Share (%), 2018 & 2025

Figure 9-1: Bahrain - Pharmaceutical Market Size - Bahrain vs. Rest of GCC (%), 2018

Figure 9-2: Bahrain - Pharmaceutical Market Size (US\$ Million), 2018 - 2025

Figure 9-3: Bahrain - Pharmaceutical Market Size - Import vs. Total Market (US\$ Million), 2018

Figure 9-4: Bahrain - Pharmaceutical market Share - Import vs. Other Market (%), 2018

Figure 9-5: Bahrain - Pharmaceutical market Share by Therapeutic Agents (%), 2018

Figure 9-6: Bahrain - Market Size by Leading Pharmaceutical Companies (US\$ Million), 2018

Figure 9-7: Bahrain - Share of Generics in Total Pharmaceutical Market (%) 2018 & 2025

Figure 9-8: Bahrain - Share of OTC in Total Pharmaceutical Market (%) 2018 & 2025

Figure 9-9: Bahrain - Patented, Generics & OTC Pharmaceuticals Market Share (%), 2018

Figure 9-10: Bahrain - Patented, Generics & OTC Pharmaceuticals Market Share (%), 2025

Figure 9-11: Bahrain - Generic Pharmaceutical Market Size (US\$ Million), 2018 & 2025

Figure 9-12: Bahrain - OTC Pharmaceutical Market Size (US\$ Million), 2018 & 2025

Figure 10-1: Qatar - Pharmaceutical Market Size (US\$ Million), 2015 - 2018

Figure 10-2: Qatar - Pharmaceutical Market Size - Qatar vs. Rest of GCC (%), 2018

- Figure 10-3: Qatar - Pharmaceutical Market Size - Qatar vs. Rest of MEA (%), 2018
- Figure 10-4: Qatar - Pharmaceutical Market Size (US\$ Million), 2018 - 2025
- Figure 10-5: Qatar - Pharmaceutical Market Size by Product Type (US\$ Million), 2018
- Figure 10-6: Qatar - Pharmaceutical Market Size by Product Type (%), 2018
- Figure 10-7: Qatar - Pharmaceutical Market Size by Type of Product (US\$ Million), 2025
- Figure 11-1: Oman - Pharmaceutical Market Size (US\$ Million), 2012, 2016 & 2018
- Figure 11-2: Pharmaceutical Market Size - Oman vs. Rest of GCC (%), 2018
- Figure 11-3: Pharmaceutical Market Size - Oman vs. Rest of MEA (%), 2018
- Figure 11-4: Oman - Pharmaceutical Market Size (US\$ million), 2019 - 2025
- Figure 11-5: Oman - Import, Export & Other Pharmaceutical Market Size (US\$ Million), 2018
- Figure 11-6: Oman - Import, Export & Other Pharmaceutical Market Size (%), 2018
- Figure 11-7: Oman - Share of Generics in Total Pharmaceutical Market (%) 2016, 2018 & 2025
- Figure 11-8: Oman - Share of OTC in Total Pharmaceutical Market (%) 2016, 2018 & 2025
- Figure 11-9: Oman - Patented, Generics & OTC Pharmaceuticals Market Share (%), 2018
- Figure 11-10: Oman - Patented, Generics & OTC Pharmaceuticals Market Share (%), 2025
- Figure 11-11: Oman - Generic Pharmaceutical Market Size (US\$ Million), 2018 & 2025
- Figure 11-12: Oman - OTC Pharmaceutical Market Size (US\$ Million), 2018 & 2025
- Figure 12-1: GCC - Pharmaceutical Import Market Size by Countries (US\$ Billion), 2018
- Figure 12-2: GCC - Pharmaceutical Import Market Size by Countries (%), 2018
- Figure 12-3: GCC - Import Pharmaceutical Market Size (US\$ Billion), 2016, 2017 & 2018
- Figure 12-4: Saudi Arabia - Pharmaceutical Import Size (US\$ Billion), 2016 - 2018
- Figure 12-5: UAE - Pharmaceutical Import Size (US\$ Billion), 2016 - 2018
- Figure 12-6: Kuwait - Pharmaceutical Import Size (US\$ Billion), 2016 - 2018
- Figure 12-7: Bahrain - Pharmaceutical Import Size (US\$ Million), 2016 - 2018
- Figure 12-8: Qatar - Pharmaceutical Import Size (US\$ Million), 2016 - 2018
- Figure 12-9: Oman - Pharmaceutical Import Size (US\$ Million), 2016 - 2018
- Figure 12-10: GCC - Pharmaceutical Export Market Size by Countries (US\$ Million), 2018
- Figure 12-11: GCC - Pharmaceutical Export Market Size by Countries (%), 2018
- Figure 12-12: GCC - Export Pharmaceutical Market Size (US\$ Billion), 2016, 2017 & 2018
- Figure 12-13: Saudi Arabia - Pharmaceutical Export Size (US\$ Million), 2016 - 2018
- Figure 12-14: UAE - Pharmaceutical Export Size (US\$ Million), 2016 - 2018

Figure 12-15: Kuwait - Pharmaceutical Export Size (US\$ Million), 2016 - 2018

Figure 12-16: Bahrain - Pharmaceutical Export Size (US\$ Million), 2016 - 2018

Figure 12-17: Qatar - Pharmaceutical Export Size (US\$ Million), 2016 - 2018

Figure 12-18: Oman - Pharmaceutical Export Size (US\$ Million), 2016 - 2018

Figure 13-1: GCC - Number of Clinical Trials by Countries, 2019

Figure 13-2: GCC - Clinical Trials by Countries (%), 2019

Figure 13-3: GCC - Number of Clinical Trials by Status, 2019

Figure 13-4: GCC - Clinical Trials by Status (%), 2019

Figure 13-5: GCC - Number of Clinical Trial by Phase, 2019

Figure 13-6: GCC - Number of Clinical Trial by Phase (%), 2019

Figure 13-7: GCC - Numbers of Clinical Trials by Indications, 2019

Figure 13-8: GCC - Clinical Trials by Indications (%), 2019

Figure 13-9: GCC - Number of Cancer Related Clinical Trials by Countries, 2019

Figure 13-10: GCC - Cancer Related Clinical Trials by Countries (%), 2019

Figure 13-11: GCC - Number of Cancer Related Clinical Trials by Phase of Development, 2019

Figure 13-12: GCC - Number of Diabetes Related Clinical Trials by Countries, 2019

Figure 13-13: GCC - Diabetes Related Clinical Trials by Countries (%), 2019

Figure 13-14: GCC - Number of Diabetes Related Clinical Trials by Development Phase, 2019

Figure 13-15: GCC - Number of CVS Disorder Related Clinical Trials by Countries, 2019

Figure 13-16: GCC - CVS Disorder Related Clinical Trials by Countries (%), 2019

Figure 13-17: GCC - Number of CVS Disorders Related Clinical Trials by Development Phase, 2019

Figure 13-18: GCC - Number of Respiratory Disorder (Except Lung Cancer) Related Clinical trials by Countries, 2019

Figure 13-19: GCC - Respiratory Disorder (Except Lung Cancer) Related Clinical Trials by Countries (%), 2019

Figure 13-20: GCC - Number of Respiratory Disorders Related Clinical Trials by Development Phase, 2019

Figure 13-21: Saudi Arabia - Number of Clinical Trials by Development Phase, 2019

Figure 13-22: Saudi Arabia - Number of Clinical Trials by Status, 2019

Figure 13-23: Saudi Arabia - Numbers of Clinical Trials by Indications, 2019

Figure 13-24: Saudi Arabia - Clinical Trials by Indications (%), 2019

Figure 13-25: UAE - Clinical Trials in States of UAE (%), 2019

Figure 13-26: UAE - Number of Clinical Trials by Development Phase, 2019

Figure 13-27: UAE - Number of Clinical Trials by Status, 2019

Figure 13-28: UAE - Numbers of Clinical Trials by Indications, 2019

- Figure 13-29: UAE - Clinical Trials by Indications (%), 2019
- Figure 13-30: Kuwait - Number of Clinical Trials by Development Phase, 2019
- Figure 13-31: Kuwait - Number of Clinical Trials by Status, 2019
- Figure 13-32: Kuwait - Numbers of Clinical Trials by Indications, 2019
- Figure 13-33: Kuwait - Clinical Trials by Indications (%), 2019
- Figure 13-34: Bahrain - Number of Clinical Trials by Development Phase, 2019
- Figure 13-35: Bahrain - Number of Clinical Trials by Status, 2019
- Figure 13-36: Qatar - Number of Clinical Trials by Development Phase, 2019
- Figure 13-37: Qatar - Number of Clinical Trials by Status, 2019
- Figure 13-38: Qatar - Numbers of Clinical Trials by Indications, 2019
- Figure 13-39: Kuwait - Clinical Trials by Indications (%), 2019
- Figure 13-40: Oman - Number of Clinical Trials by Development Phase, 2019
- Figure 13-41: Oman - Number of Clinical Trials by Status, 2019
- Figure 14 1: Driving Factors for GCC Pharmaceutical Market
- Figure 15-1: Challenges for GCC Pharmaceutical Market
- Figure 16-1: GCC - Population Forecast by Countries (Million), 2025
- Figure 16-2: GCC - Pharmaceutical Market Forecast by Countries (US\$ Billion), 2025
- Figure 16-3: GCC - Pharmaceutical Market Share Forecast by Countries (%), 2025
- Figure 16-4: GCC - Cancer Drug Market Forecast (US\$ Billion), 2018 & 2025
- Figure 16-5: GCC - Generic Pharmaceutical Market Forecast (%), 2025

I would like to order

Product name: GCC Pharmaceutical Market Opportunity Insight 2025

Product link: <https://marketpublishers.com/r/G59FEC836F10EN.html>

Price: US\$ 3,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G59FEC836F10EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970